The global amiodarone market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Amiodarone is also known as an anti-arrhythmic drug. It is a medication that is used to treat certain types of serious irregular heartbeat such as persistent ventricular fibrillation/tachycardia. Additionally, It restores normal heart rhythm and supports to maintain a regular steady heartbeat and works by blocking certain electrical signals in the heart that can cause an irregular heartbeat. The major factor driving the demand for amiodarone is the rising incidence of cardiac arrest across the globe. 

According to the American Heart Association report, Heart and Stroke Statistics - 2022 Update, cardiac arrest remains a public health crisis with more than 356,000 out-of-hospital cardiac arrests (OHCA) annually in the US, out of which nearly 90% of them fatal. Additionally, the incidence of EMS-assessed non-traumatic OHCA in people of any age is estimated to be 356,461, or nearly 1,000 people each day. Hence, the increasing prevalence of cardiac arrest is driving the demand for amiodarone for treatment as it stabilizes the heartbeat which in turn is driving the growth of the market.

Some major players in the market include Sanofi SA, Mylan NV, and GlaxoSmithKline plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2020, Unichem Laboratories announced that it has received approval from the US FDA for Amiodarone tablets, the generic version of Wyeth Pharmaceuticals Inc's Cordarone tablets for the treatment of an irregular heartbeat. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Sanofi SA, Mylan NV, and GlaxoSmithKline plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Amiodarone Market Report by Segment

By Type

• Tablet
• Capsule 
• Injection

By Application 

• Cardiac Arrest
• Ventricular Tachycardia
• Atrial Fibrillation
• Others

Global Amiodarone Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa